References
- Eiken P ,Kolthoff N ,Nielsen S P. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996; 19: 191S–3S
- Devogelaer J P ,Broil H ,Correa-Rotter R ,et al. Oral alendronate induces progressive increases in bone mass of the spine ,hip ,and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996; 18: 141–50
- Arnala I ,Saastamoinen J ,Alhava E M. Salmon calcitonin in the prevention of bone loss at perimenopause. Bone 1996; 18: 629–32
- Bröll H. Consensus statement: osteoporosis ,classification and clinical features. Rheumatol Europe 1996; 25/1: 33–6
- Kaufman J M. Role of calcium and vitamin D in the prevention and the treatment of postmenopausal osteoporosis: an overview. Clin Rheum 1995; 14: 9–13
- Dambacher M A ,Kranich M ,Schacht E ,et al. Can the fast bone loss in osteoporotic and osteopenic patients be stopped with active vitamin D metabolites?. Calcif Tissue Int 1997; 60: 115–18
- Hata H ,Miura M. Evaluation of an immunoassay method for determination of urinary collagen crosslink excretion. Ann Clin Biochem 1994; 31: 374–5
- Garnero P ,Delmas P D. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996; 59: S2–S9
- Delmas P O ,Schlemmer A ,Riis B J ,et al. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured in illiae crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991; 6: 639–44
- Peichl P ,Zammani O ,Kumpan W ,et al. Antiosteoporotic therapy with monofluorophosphate and calcium increases cortical and trabecular vertebral bone density. Osteologie 1995; 4: 87–98
- Schneider P ,Butz S ,Allolio B ,et al. Multicenter German reference database for peripheral quantitative computer tomography. Technol Health Care 1995; 2: 369–73
- Jergas M ,Genant H. Current methods and recent advances in the diagnosis of osteoporosis. Arthrit Rheum 1993; 36: 1649–62
- Van Riel R. Provisional guidelines for measuring disease activity in RA clinical trials. Br J Rheumatol 1992; 31: 793–4
- Gennari C ,Agnusdei D ,Montagnani M ,et al. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tiss Int 1992; 50: 381–3
- Reginster Y. Calcitonin for prevention and treatment of osteoporosis. Am J Med 1995; 2: 44S–47S
- Kanis J A ,Johnell O ,Gulberg B ,et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 1992; 305: 1124–8
- Chambers T J ,Azaria M. The effect of calcitonin on the osteoclast. Traingle Sandoz 1988; 27: 53–60
- Welzel K ,Welzel D. Die Erhöhung der Schmerzschwelle durch Calcitonin. Der Schmerz 1989; 3: 118–32
- Gennari C ,Agnusdei D ,Cepollaro C ,et al. Effect on bone mass and bone turnover of a 2-year intermittent or continuous treatment with salmon calcitonin nasal spray in postmenopausal osteoporotic patients. Proceedings of the 11th International Conference on Calcium Regulating Hormones. Osteoporosis Int 1992; 11: 400–6
- Overgaard K ,Christiansen C. A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin. Calcif Tiss Int 1996; 59: 12–16
- Overgaard K ,Hansen M A ,Herss Nielsen V ,et al. Discontinuous calcitonin treatment of established osteoporosis: effects of withdrawal of treatment. Am J Med 1990; 89: 1–6
- Thamsborg G ,Jensen J E ,Kollerup G ,et al. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 1996; 18: 207–12
- Lyritis G P ,Magiasis B ,Tsalakos N. Non-osteoporotic high turnover patients with salmon calcitonin. The role of biochemical bone markers in monitoring high turnover patients and calcitonin treatment. Calcif Tiss Int 1995; 56: 38–41
- Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tiss Int 1994; 55: 82–6